Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ELI-002 7P |
| Trade Name | |
| Synonyms | ELI-0027P|ELI-002-7P|ELI002 7P |
| Drug Descriptions |
ELI-002 7P is a cancer vaccine comprising Amphiphile-modified KRAS G12D, G12R, G12V, G12C, G12A, G12S and G13D peptides, which potentially induces antitumor immune response against KRAS mutant tumor cells (Journal for ImmunoTherapy of Cancer 2024; 12, Suppl 3). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | NA |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ELI-002 7P | ELI-002 7P | 0 | 0 |
| ELI-002 7P + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | ELI-002 7P Fluorouracil Irinotecan Leucovorin Oxaliplatin | 0 | 1 |
| ELI-002 7P + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + Tislelizumab | ELI-002 7P Fluorouracil Irinotecan Leucovorin Oxaliplatin Tislelizumab | 0 | 1 |